MannKind reported $48.47M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Adma Biologics USD 266.12M 26.8M Sep/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Halozyme Therapeutics USD 132.61M 4.52M Sep/2026
Insmed USD 163.95M 21.56M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
MannKind USD 48.47M 4.05M Sep/2026
Merck USD 6.16B 43M Sep/2026
Novavax USD 18.5M 8.49M Sep/2026
Novo Nordisk DKK 51.35B 8.5B Mar/2026
Pfizer USD 10.02B 77M Sep/2026
Sanofi EUR 24.12B 620M Jun/2026